



## Contineum Therapeutics to Present at September Investor Conferences

August 28, 2025

SAN DIEGO--(BUSINESS WIRE)--Aug. 28, 2025-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the following investor conferences in September.

**Cantor Global Healthcare Conference 2025** – fireside chat on Thursday, September 4, 2025, at 9:10 a.m. ET.

**Morgan Stanley 23rd Annual Global Healthcare Conference** – fireside chat on Monday, September 8, 2025, at 8:30 a.m. ET.

**Baird 2025 Global Healthcare Conference** – fireside chat on Tuesday, September 9, 2025, at 2:00 p.m. ET.

An audio webcast of the presentations can be accessed on the [Investors](#) section of Contineum’s website. A replay of the webcasts will also be available.

### **About Contineum Therapeutics**

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder. For more information, please visit [www.contineum-tx.com](http://www.contineum-tx.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250828059102/en/): <https://www.businesswire.com/news/home/20250828059102/en/>

Steve Kunszabo  
Contineum Therapeutics  
Senior Director, Investor Relations & Corporate Communications  
858-649-1158  
[skunszabo@contineum-tx.com](mailto:skunszabo@contineum-tx.com)

Source: Contineum Therapeutics, Inc.